Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for pediatric portal hypertension and variceal bleeding in compensated cirrhosis
IRCT20230301057580N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in Portal Hypertension (PH) and esophageal varices (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Portal hemodynamic indices on Doppler sonography, Esophageal varices grade and 1 more. Started Nov 2024; status: completed.
02
Drugs
rosuvastatin
03
Conditions
Portal Hypertension (PH)esophageal varices
Beyond the preview
Go deeper on IRCT20230301057580N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230301057580N1.